


RealRate

PHARMACEUTICAL 2019

PLx Pharma Inc. Rank 59 of 371









RealRate

PLx Pharma Inc. Rank 59 of 371



The relative strengths and weaknesses of PLx Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PLx Pharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 369% points. The greatest weakness of PLx Pharma Inc. is the variable Revenues, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 402% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	14,865
Cost of Goods Sold	0
Intangible Assets	2,061
Liabilities, Current	4,733
Liabilities, Non-Current	4,365
Other Assets	68
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	2,847
Other Net Income	11,858
Property and Equipment	1,394
Research and Development	3,923
Revenues	753
Selling, General and Administrative Expense	7,792

Output Variable	Value in 1000 USD
Assets	18,388
Liabilities	11,944
Expenses	11,714
Stockholders Equity	6,444
Net Income	896
Comprehensive Net Income	896
Economic Capital Ratio	71%

